Omaveloxolone
Phase 1Recruiting 0 watching 0 views this week๐ค Quiet
30
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Jul 1, 2024 โ Nov 22, 2030
NCT ID
NCT06054893About Omaveloxolone
Omaveloxolone is a phase 1 stage product being developed by Biogen for Friedreich Ataxia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06054893. Target conditions include Friedreich Ataxia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03593499 | Pre-clinical | Completed |
| NCT06628687 | Pre-clinical | Recruiting |
| NCT07297199 | Phase 1 | Recruiting |
| NCT07019064 | Phase 1 | Completed |
| NCT06623890 | Pre-clinical | Recruiting |
| NCT06612879 | Phase 1 | Completed |
| NCT06054893 | Phase 1 | Recruiting |
| NCT03664453 | Phase 1 | Completed |
Competing Products
20 competing products in Friedreich Ataxia